Genomics, the data revolution and health economics – the 2015 Astellas Innovation Debate

Last week I attended the Astellas Innovation Debate (“i-Genes: What the DNA and Data revolutions mean for our health”) at the Royal Institution of Great Britain in London. This was an interesting event and I was pleased to get the opportunity to make a couple of points during the debate itself. I also wrote about the debate and the wider implications of this revolution from a health economics perspective for the BMJ. You can read this blog here.

Interested readers can watch the entire 2015 debate at


Hello. Chances are you’re a health economist, although you might also be a researcher in a different field of healthcare. You might even be a scientist (apologies in advance for any bad science that might follow). Whoever you are, you’re very welcome. The aim of this introductory post is to tell you what you should expect from this blog. Hopefully you’ll be sufficiently intrigued to return, read some more articles and contribute to the growing debate surrounding the application of standard health economic methods in the field of genomics.

This blog is going to assume that you know a little bit about genomics. Specifically, this blog is going to assume that you have at least read the “What are genomic technologies?” section of this blog, a short introduction for a layperson who already has a little bit of science knowledge. Of course, many of you will have a greater knowledge of genetics and genomics than this simple introduction, but this blog is intended to be broadly accessible to stimulate wide debate, so the aim is to keep the genomics jargon to a minimum. This blog is also going to assume that the average reader has some basic knowledge about health economics. Those who don’t could do a lot worse than frequent the excellent “Academic Health Economists’ Blog”.

Continue reading